Logo image of PHVS

PHARVARIS NV (PHVS) Stock Fundamental Analysis

USA - NASDAQ:PHVS - NL00150005Y4 - Common Stock

24.95 USD
+0.69 (+2.84%)
Last: 9/30/2025, 8:00:01 PM
24.95 USD
0 (0%)
After Hours: 9/30/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, PHVS scores 2 out of 10 in our fundamental rating. PHVS was compared to 196 industry peers in the Pharmaceuticals industry. PHVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHVS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PHVS had negative earnings in the past year.
PHVS had a negative operating cash flow in the past year.
PHVS had negative earnings in each of the past 5 years.
In the past 5 years PHVS always reported negative operating cash flow.
PHVS Yearly Net Income VS EBIT VS OCF VS FCFPHVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

PHVS's Return On Assets of -80.21% is on the low side compared to the rest of the industry. PHVS is outperformed by 71.94% of its industry peers.
PHVS has a Return On Equity (-91.30%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -80.21%
ROE -91.3%
ROIC N/A
ROA(3y)-38.96%
ROA(5y)-32.55%
ROE(3y)-42.51%
ROE(5y)-35.1%
ROIC(3y)N/A
ROIC(5y)N/A
PHVS Yearly ROA, ROE, ROICPHVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

PHVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHVS Yearly Profit, Operating, Gross MarginsPHVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for PHVS has been increased compared to 1 year ago.
The number of shares outstanding for PHVS has been increased compared to 5 years ago.
The debt/assets ratio for PHVS is higher compared to a year ago.
PHVS Yearly Shares OutstandingPHVS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PHVS Yearly Total Debt VS Total AssetsPHVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PHVS has an Altman-Z score of 27.50. This indicates that PHVS is financially healthy and has little risk of bankruptcy at the moment.
PHVS has a Altman-Z score of 27.50. This is amongst the best in the industry. PHVS outperforms 94.90% of its industry peers.
PHVS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PHVS (0.00) is better than 62.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.5
ROIC/WACCN/A
WACCN/A
PHVS Yearly LT Debt VS Equity VS FCFPHVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 8.33 indicates that PHVS has no problem at all paying its short term obligations.
PHVS's Current ratio of 8.33 is fine compared to the rest of the industry. PHVS outperforms 78.57% of its industry peers.
A Quick Ratio of 8.33 indicates that PHVS has no problem at all paying its short term obligations.
The Quick ratio of PHVS (8.33) is better than 78.57% of its industry peers.
Industry RankSector Rank
Current Ratio 8.33
Quick Ratio 8.33
PHVS Yearly Current Assets VS Current LiabilitesPHVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PHVS have decreased strongly by -28.22% in the last year.
EPS 1Y (TTM)-28.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHVS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.56% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-15.76%
EPS Next 2Y-5.48%
EPS Next 3Y6.02%
EPS Next 5Y20.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHVS Yearly Revenue VS EstimatesPHVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHVS Yearly EPS VS EstimatesPHVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHVS Price Earnings VS Forward Price EarningsPHVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHVS Per share dataPHVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.48%
EPS Next 3Y6.02%

More info and screens

0

5. Dividend

5.1 Amount

PHVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARVARIS NV

NASDAQ:PHVS (9/30/2025, 8:00:01 PM)

After market: 24.95 0 (0%)

24.95

+0.69 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners50.36%
Inst Owner Change-0.43%
Ins Owners5.32%
Ins Owner ChangeN/A
Market Cap1.60B
Analysts85.88
Price Target33.94 (36.03%)
Short Float %0.97%
Short Ratio2.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.38%
Min EPS beat(2)-9.19%
Max EPS beat(2)-5.58%
EPS beat(4)1
Avg EPS beat(4)-6.35%
Min EPS beat(4)-23.64%
Max EPS beat(4)12.99%
EPS beat(8)4
Avg EPS beat(8)-5.98%
EPS beat(12)7
Avg EPS beat(12)-3.82%
EPS beat(16)11
Avg EPS beat(16)5.52%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.55%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)17.82%
EPS NY rev (1m)2.7%
EPS NY rev (3m)8.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.38
P/tB 7.38
EV/EBITDA N/A
EPS(TTM)-3.63
EYN/A
EPS(NY)-3.24
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.5
OCFYN/A
SpS0
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -80.21%
ROE -91.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.96%
ROA(5y)-32.55%
ROE(3y)-42.51%
ROE(5y)-35.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 178.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.33
Quick Ratio 8.33
Altman-Z 27.5
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)104.84%
Cap/Depr(5y)175.41%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50.91%
EPS Next Y-15.76%
EPS Next 2Y-5.48%
EPS Next 3Y6.02%
EPS Next 5Y20.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-42.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.2%
EBIT Next 3Y-4.38%
EBIT Next 5YN/A
FCF growth 1Y-68.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.14%
OCF growth 3YN/A
OCF growth 5YN/A